Using the industry peer median P/E Multiples multiple (trailing + forward), Niagen Bioscience Inc (NAGE) has a fair value of $0.99 based on 3 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing P/E | Forward P/E | |
|---|---|---|---|
| Niagen Bioscience IncNAGE | 356 | 20.8x | 104.3x |
| Zevra Therapeutics, Inc. | 650 | 8.1x | 22.6x |
| Rigel Pharmaceuticals, Inc. | 485 | 1.3x | 6.5x |
| Keros Therapeutics, Inc. | 449 | 5.2x | — |
| Industry Median | 5.2x | 14.6x | |
| (*) Profit after tax | 17 | 3 | |
| Equity Value | 91 | 77 | |
| (/) Outstanding shares | 85 | 85 | |
| Fair Price | $1 | $1 | |
Using the industry peer median EV/EBITDA multiple (trailing + forward), Niagen Bioscience Inc (NAGE) has a fair value of $1.55 based on 4 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/EBITDA | Forward EV/EBITDA | |
|---|---|---|---|
| Niagen Bioscience IncNAGE | 356 | 18.7x | 24.9x |
| Zevra Therapeutics, Inc. | 650 | 6.6x | 4.9x |
| Rigel Pharmaceuticals, Inc. | 485 | 3.9x | 4.1x |
| Keros Therapeutics, Inc. | 449 | 2.5x | — |
| Akebia Therapeutics, Inc. | 311 | 15.8x | 16.4x |
| Industry Median | 5.2x | 4.9x | |
| (*) EBITDA | 16 | 12 | |
| = Enterprise Value | 83 | 58 | |
| (-) Net Debt | -62 | -62 | |
| Equity Value | 145 | 120 | |
| (/) Outstanding shares | 85 | 85 | |
| Fair Price | $2 | $1 | |
Using the industry peer median EV/Revenue multiple (trailing + forward), Niagen Bioscience Inc (NAGE) has a fair value of $5.88 based on 7 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Niagen Bioscience IncNAGE | 356 | 2.3x | 3.0x |
| KalVista Pharmaceuticals, Inc. | 1,369 | 18.6x | 6.9x |
| Zevra Therapeutics, Inc. | 650 | 6.1x | 4.5x |
| Prothena Corporation plc | 566 | 28.2x | 3.1x |
| REGENXBIO Inc. | 538 | 4.5x | 3.0x |
| Rigel Pharmaceuticals, Inc. | 485 | 1.7x | 1.8x |
| Keros Therapeutics, Inc. | 449 | 0.7x | 50.0x |
| Akebia Therapeutics, Inc. | 311 | 1.5x | 1.5x |
| Industry Median | 4.5x | 3.1x | |
| (*) Revenue | 129 | 97 | |
| = Enterprise Value | 580 | 301 | |
| (-) Net Debt | -62 | -62 | |
| Equity Value | 642 | 363 | |
| (/) Outstanding shares | 85 | 85 | |
| Fair Price | $8 | $4 | |
Using the PEG framework with analyst consensus forward EPS growth of 23.9%, the company has a fair value of $5.76 based on NTM EPS (FY2026) of $0.24. The current PEG ratio is 0.72.
PEG < 1 = bargain, 1–1.5 = fair, > 2 = expensive.
PEG is most informative for high-growth companies — the PEG sweet spot.
| EPS Growth RateForward | 23.9% |
| Adjusted Growth (clamped 8–25%) | 23.9% |
| Fair P/E | 23.9x |
| NTM EPS (FY2026) | $0.24 |
| Fair Value | $5.76 |
| Period | EPS Est. | Growth | Analysts |
|---|---|---|---|
| FY2025 (actual) | $0.20 | — | — |
| FY2026E | $0.24 | +20.3% | 4 |
| FY2027E | $0.31 | +27.6% | 3 |
2Y Forward EPS CAGR: 23.9%
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $-27.1M | $-0.40 | — |
| FY2022 | $-16.5M | $-0.24 | — |
| FY2023 | $-4.9M | $-0.07 | — |
| FY2024 | $8.6M | $0.11 | — |
| FY2025 | $17.4M | $0.20 | +81.8% |
4Y Historical EPS CAGR: 81.8%
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.